-

PerkinElmer Expands Automated Mycotoxin Detection Kits Portfolio to Include All Major Mycotoxins

New MaxSignal Mycotoxin Automation Bundle enables faster time to result, lower cost per sample and increased productivity

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced the launch of its MaxSignal® Mycotoxin Automation Bundle. Using the new assays and automation of this bundle, food safety QA managers and lab teams at grain processors, feed mills, pet food companies and contract labs can accurately and efficiently process up to 180 samples in less than 90 minutes.

The new bundle – comprised of four powerful kits: MaxSignal HTS Zearalenone ELISA Kit, MaxSignal HTS Fumonisin ELISA Kit, MaxSignal HTS Ochratoxin A ELISA Kit, and MaxSignal HTS T2/HT2 ELISA Kit – joins the Deoxynivalenol (DON) and Total Aflatoxin automation kits released by the Company last year. PerkinElmer’s portfolio covers both phases of mycotoxin testing: screening and confirmation tests. This offering includes complete workflows from screening to analytical confirmation, integration software and application support to develop new methods and improve existing method performance.

In addition to significant improvement in sample throughput, these automated solutions are designed to handle complex matrices with high sensitivity and accuracy. The workflow is intended to be “set it and forget it” to minimize the need for human intervention, reduce the risk of manual error and help customers meet regulatory standards.

“Mycotoxin testing has always been a critical facet of the workflow for high volume food processors and has traditionally required significant investments in time and labor,” said Greg Sears, vice president and general manager, food segment and organic mass spectrometry. “With our new MaxSignal Mycotoxin Automation Bundle, we are combining better and faster solutions with lower total cost per sample for intricate food matrices. This innovation creates faster times to result, absorbing spikes in regional demand and helping customers realize higher lab productivity.”

To learn more about this offering, click here. For additional information about PerkinElmer’s innovations across food safety and quality analysis, visit: https://www.perkinelmer.com/category/food-safety-quality.

About PerkinElmer

PerkinElmer enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food, and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the well-being and longevity of people globally. The Company reported revenue of approximately $3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

Contacts

Media:
Adriana Howell
adriana.howell@perkinelmer.com
765-918-3070

PerkinElmer, Inc.


Release Summary
PerkinElmer launches its MaxSignal® Mycotoxin Automation Bundle to accurately and efficiently process up to 180 samples in less than 90 minutes.
Release Versions

Contacts

Media:
Adriana Howell
adriana.howell@perkinelmer.com
765-918-3070

More News From PerkinElmer, Inc.

PerkinElmer Launches Cloud Based Solution to Enable Remote Lab Management

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced the launch of its PKeye™ Workflow Monitor, a cloud-based platform enabling laboratory personnel to remotely manage and monitor their PerkinElmer instruments and workflows in real-time. The PKeye Workflow Monitor offers scientists and researchers 24/7 access and visibility into their laboratory operations. With a cloud-based web design and centralized summary dashboa...

PerkinElmer Releases 2021 Corporate Social Responsibility Report

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader innovating for a healthier world, today released its 2021 Corporate Social Responsibility (CSR) Report, which summarizes the latest achievements of its environmental, social and governance (ESG) program. The report titled, “Strengthening Our Commitments for Sustainable Impact,” also outlines four new ESG commitments unveiled by the Company earlier this year and describes its reporting framework established in accord...

PerkinElmer Receives FDA Emergency Use Authorization for Respiratory SARS-CoV-2 Panel

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel 1 assay. Qualified laboratories can immediately begin using this single test for the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus (RSV) isolated from nasopharyngeal swabs, anterior nasal swabs...
Back to Newsroom